starpharma

ASX Announcement

# Successful Completion of $32 million Entitlement Offer

**Melbourne, Australia; 11 August 2026: Starpharma Holdings Limited** (ASX: SPL, US OTC: SPHRY) (**Starpharma** or the **Company**) today announces the successful completion of the fully underwritten 1 for 7.5 renounceable pro rata entitlement offer (**Entitlement Offer**) of new fully paid ordinary shares in the Company (**New Shares**) to raise $32 million (before costs), details of which were announced on 15 July 2026.

The Entitlement Offer closed at 5.00 p.m. (AEST) on Tuesday, 4 August 2026, receiving strong support from existing shareholders with a take-up rate of approximately 99%, including $5.4 million of applications under the Oversubscription Facility. The Underwriter of the Entitlement Offer, Canaccord Genuity (Australia) Limited, will subscribe for, or procure subscriptions for, $0.5 million in shortfall shares in accordance with the Underwriting Agreement.

Eligible shareholders who applied for New Shares under the Oversubscription Facility can expect to receive the full quantum of their applications.

56,126,514 New Shares issued under the Entitlement Offer are expected to be allotted today, 11 August 2026, and will rank equally with existing Starpharma shares as at their date of issue.

Rights of ineligible foreign shareholders were sold on-market by the nominee, and net proceeds will be distributed on 14 August 2026.

The Board is very pleased with this outcome and thanks all participants for their support.

Over the past 12 months, Starpharma has built strong momentum across its portfolio, including advancing its DEP® HER2-Lutetium program, progressing strategic partnerships, and strengthening its internal discovery pipeline. The proceeds from the Entitlement Offer will support the planned first-in-human and dose escalation stages of the DEP® HER2-Lu Phase 1 study, as well as the advancement of additional DEP® oncology assets. Starpharma is well placed to build on recent momentum, with a strategic focus on building a high-value pipeline of targeted oncology assets and generating long-term value for shareholders.

All documents relating to the Entitlement Offer can be accessed on Starpharma's website at: https://starpharma.com/entitlement-offer.

**About Starpharma**

Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.

**Investor & Media Relations**
Gabriella Hold
gaby@thecapitalnetwork.com.au

**Starpharma Holdings Limited**
Cheryl Maley, Chief Executive Officer
Justin Cahill, Chief Financial and Operations Officer and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford VIC 3067

**Disclosure**
This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

**Forward-Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.